Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study

Vaxart (VXRT) Says New Data from Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

May 3, 2021 5:07 PM EDT

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today at Vaxarts key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the companys first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity.

We have previously announced study data showing that our oral vaccine could be as protective as the... More

Pre-Open Stock Movers 05/03: (MDP) (OCGN) (VIRX) Higher; (VXRT) (PETS) (EL) Lower (more...)

May 3, 2021 9:30 AM EDT

Today's Pre-Open Stock Movers

Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) 33% HIGHER; adds to recent momentum gains.

Meredith Corporation (NYSE: MDP) 12.5% HIGHER; today announced that it has agreed to sell its Local Media Group ("LMG") to Gray Television, Inc. (NYSE: GTN) for $2.7 billion in cash and will focus exclusively on its... More

Vaxart (VXRT) Reports Q1 Loss of $0.14/sh

May 3, 2021 8:03 AM EDT

Vaxart (NASDAQ: VXRT) reported Q1 EPS of ($0.14), versus ($0.02) reported last year. Revenue for the quarter came in at $506 thousand, versus $2.9 million reported last year.

For earnings history and earnings-related data on Vaxart (VXRT) click here.

... More